Table 2.
Clinical characteristics of GMPP and RMPP
| Characteristics | GMPP (n = 51) | RMPP (n = 56) | P value |
|---|---|---|---|
| Age (y) | 3.679 ± 3.193 | 4.805 ± 3.322 | 0.077 |
| Gender (male/female) | 27/51 | 28/56 | 0.847 |
| Clinical presentation | |||
| Wheezing, No. (%) | 7(13.73) | 13(23.21) | 0.227 |
| Hypoxemia, No. (%) | 4(7.84) | 12(21.43) | 0.060 |
| Duration of fever (d) | 4.784 ± 2.831 | 10.339 ± 6.473 | < 0.001 |
| Duration of wheezing (d) | 0.00(0.00,5.00) | 0.00(0.00,7.00) | 0.459 |
| Extrapulmonary complications, No. (%) | 6(11.76) | 12(23.21) | 0.137 |
| Imaging features, No. (%) | |||
| Consolidation, No. (%) | 22(43.14) | 37(66.07) | 0.02 |
| Interstitial changes, No. (%) | 26(50.98) | 16(28.57) | 0.029 |
| Laboratory detection | |||
| White blood cell count (*109/L) | 9.583 ± 3.348 | 8.420 ± 3.530 | 0.084 |
| Lymphocyte percentage (%) | 37.291 ± 14.817 | 32.352 ± 14.690 | 0.088 |
| C-reactive protein (mg/l) | 12.00(8.00,25.00) | 11.00(5.00,25.75) | 0.664 |
| ESR (mm/h) | 29.11 ± 19.935 | 37.88 ± 22.412 | 0.045 |
| Coinfection, No. (%) | 28(54.90) | 32(57.14) | 0.847 |
| Coinfection with adenovirus, No. (%) | 6(11.76) | 18(32.14) | 0.019 |
| A2063G mutation, No. (%) | 20(39.22) | 40(71.43) | 0.001 |
| Treatment | |||
| No fever within 48 h after application of macrolides, No. (%) | 6(11.76) | 50(89.29) | < 0.001 |
| Application of glucocorticoids, No. (%) | 24(47.06) | 44(78.57) | 0.001 |
| Mechanical ventilation, No. (%) | 4(7.84) | 3(5.36) | 0.707 |
Data are No. (%) of patients, mean ± standard deviation (SD) or median (interquartile range)
Abbreviation: General Mycoplasma pneumoniae pneumonia (GMPP); refractory Mycoplasma pneumoniae pneumonia (RMPP)